Skip to main content
Clinical Trials/IRCT20230801059005N1
IRCT20230801059005N1
Recruiting
Phase 3

Evaluation the outcomes of major adverse cardiac events after six-month colchicine consumption in the patients with ST-elevation myocardial infarction that underwent primary percutaneous coronary intervention.

Shiraz University of Medical Sciences0 sites204 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Shiraz University of Medical Sciences
Enrollment
204
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients who had experienced ST\-elevation myocardial infarction (STEMI)
  • In angiography of patients, in at least one of the epicardial arteries larger than or equal to two and a half millimeters, there should be a stenosis equal to or greater than fifty percent, which has been managed through percutaneous coronary intervention and medical therapy.
  • patients were undergoing percutaneous coronary intervention (PCI).

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials